Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program

SUMMIT, N.J.--(Healthcare Sales & Marketing Network)-- Celgene Corporation (NASDAQ: CELG) today announced that the GED-0301 (mongersen) phase III REVOLVE trial (CD-002) in Crohn's disease (CD) and the extension trial (SUSTAIN, CD-004) will discontinue. Cel... Biopharmaceuticals, Gastroenterology Celgene, mongersen, REVOLVE trial, Crohn's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news